Wegovy and Ozempic are two of the most discussed weight loss medications, and for good reason - they both contain semaglutide, a highly effective GLP-1 receptor agonist. But despite both being semaglutide-based, these medications have important differences in their approved uses, dosing, and intended purposes. Understanding these differences is essential for choosing the right option for your weight loss journey.
The Bottom Line: Key Differences
| Feature | Wegovy | Ozempic |
|---|---|---|
| FDA Approval | Chronic weight management | Type 2 diabetes |
| Maximum Dose | 2.4mg weekly | 2mg weekly |
| Average Weight Loss | Clinically significant | Meaningful |
| Titration Period | 16-20 weeks | 8-12 weeks |
| Dose Steps | 0.25, 0.5, 1, 1.7, 2.4mg | 0.25, 0.5, 1, 2mg |
| Manufacturer | Novo Nordisk | Novo Nordisk |
Same GLP-1 Receptor Agonist, Different Purposes
Both Wegovy and Ozempic contain semaglutide, manufactured by Novo Nordisk. The key difference lies in what they are designed and approved for:
Wegovy: Designed for Weight Loss
Wegovy received FDA approval in 2021 specifically for chronic weight management in adults with:
- BMI of 30 or higher (obesity), or
- BMI of 27 or higher with at least one weight-related condition (high blood pressure, type 2 diabetes, high cholesterol)
Because Wegovy was developed for weight loss from the start, it was optimized with a higher maximum dose (2.4mg vs 2mg) and additional intermediate doses to allow for more gradual titration.
Ozempic: Designed for Diabetes
Ozempic received FDA approval in 2017 for improving blood sugar control in adults with type 2 diabetes. While weight loss is a common and beneficial side effect, it is not the medication's primary purpose.
When used for diabetes, the 1mg or 2mg dose is typically sufficient for blood sugar control, so there was no need to develop a higher dose. Many people use Ozempic off-label for weight loss, though this means accepting a lower maximum dose.
Dosing Differences Explained
The dosing schedules for Wegovy and Ozempic differ significantly, reflecting their different purposes.
Wegovy Dosing Schedule
| Weeks | Dose |
|---|---|
| 1-4 | 0.25mg |
| 5-8 | 0.5mg |
| 9-12 | 1mg |
| 13-16 | 1.7mg |
| 17+ | 2.4mg (maintenance) |
The 1.7mg dose is unique to Wegovy and provides an extra step between 1mg and the maximum dose, helping to minimize side effects. For complete details, see our semaglutide dosing guide.
Ozempic Dosing Schedule
| Weeks | Dose |
|---|---|
| 1-4 | 0.25mg |
| 5-8 | 0.5mg |
| 9+ | 1mg (can increase to 2mg if needed) |
Ozempic's schedule is shorter because diabetes treatment typically doesn't require the highest weight-loss doses. See our Ozempic dosage guide for more details.
Weight Loss Comparison
The difference in maximum dose translates to different weight loss outcomes.
Wegovy Weight Loss (Published Clinical Studies)
- Clinically significant average weight loss at 68 weeks
- The vast majority of participants lost at least 5% of body weight
- A significant proportion achieved 10% or greater weight loss
- Many participants achieved major weight reduction
- One-third achieved 20% or greater weight loss
Ozempic Weight Loss
- At 1mg dose: approximately 10-12% average weight loss
- At 2mg dose: approximately 13-15% average weight loss
- Weight loss is a secondary outcome in diabetes trials
- Results are impressive but slightly lower than Wegovy's higher dose
The 0.4mg difference between Ozempic's maximum (2mg) and Wegovy's maximum (2.4mg) appears to contribute a meaningful difference in weight loss - roughly 2-3% additional body weight on average.
For detailed expectations, see our GLP-1 weight loss timeline.
Side Effects Comparison
Since both medications contain semaglutide, their side effect profiles are virtually identical. The main difference is that Wegovy's higher dose may cause more pronounced effects in some people.
Common Side Effects (Both)
- Nausea (most common, especially early in treatment)
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
- Decreased appetite
- Headache
The gradual titration schedule for both medications is designed to minimize these effects. For management strategies, see our guide to managing GLP-1 nausea.
Which Should You Choose?
Choose Wegovy If:
- Your primary goal is weight loss
- You want access to the higher 2.4mg dose
- You prefer the more gradual titration schedule (extra 1.7mg step)
- You want an FDA-approved weight loss medication
- You do not have type 2 diabetes (or it's well-controlled with other medications)
Choose Ozempic If:
- You have type 2 diabetes and want the metabolic benefits
- Wegovy is not available or affordable in your area
- You're satisfied with slightly lower maximum dosing
- You want to start with a lower maximum dose before potentially switching
- Your healthcare provider recommends it for your specific situation
Can You Switch Between Them?
Yes, switching between Wegovy and Ozempic is possible since they are both semaglutide-based GLP-1 medications. Common scenarios include:
- Ozempic to Wegovy: To access the higher 2.4mg dose for more weight loss
- Wegovy to Ozempic: If Wegovy becomes unavailable or too expensive
- Any direction: Based on tolerance or healthcare provider recommendation
When switching, you typically transition directly to the equivalent dose without needing to re-titrate from the beginning. Consult with your healthcare provider for specific guidance.
Availability in Nigeria
Neither brand-name Wegovy nor Ozempic is currently registered with NAFDAC for sale in Nigeria. However, compounded semaglutide is available through licensed providers.
The advantage of compounded semaglutide is that it can be dosed according to either the Wegovy or Ozempic protocol - meaning you can access the full 2.4mg dose even without brand-name Wegovy.
For more information on accessing semaglutide in Nigeria, see our guides on how to get GLP-1 medications and GLP-1 costs.
How Do They Compare to Tirzepatide?
Tirzepatide (sold as Mounjaro and Zepbound) is a newer medication that targets both GLP-1 and GIP receptors. In published comparisons, tirzepatide has shown greater weight loss than semaglutide, owing to its dual receptor mechanism.
For a detailed comparison, see our tirzepatide vs semaglutide guide.
Conclusion
Wegovy and Ozempic are both effective semaglutide-based GLP-1 medications. The main differences are:
- Wegovy is FDA-approved for weight loss; Ozempic is approved for diabetes
- Wegovy offers a higher maximum dose (2.4mg vs 2mg)
- Wegovy typically produces more weight loss due to the higher dose
- Wegovy has a more gradual titration with an additional 1.7mg step
For most people whose primary goal is weight loss, Wegovy or Wegovy-equivalent dosing with compounded semaglutide is the preferred option. However, Ozempic remains an effective alternative, particularly for those with diabetes or when Wegovy is unavailable.